Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1977 1
1978 1
1980 1
1981 2
1982 2
1983 2
1986 2
1987 2
1989 1
1991 2
1992 3
1993 2
1995 1
1996 1
1997 1
1998 4
2000 2
2001 3
2002 3
2004 2
2005 2
2006 2
2007 2
2008 4
2009 4
2010 6
2011 3
2012 4
2013 4
2014 3
2015 6
2016 7
2017 6
2018 5
2019 8
2020 9
2021 13
2022 7
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Primary release disorder of platelets"
Page 1
AGA Clinical Practice Update: Coagulation in Cirrhosis.
O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. O'Leary JG, et al. Gastroenterology. 2019 Jul;157(1):34-43.e1. doi: 10.1053/j.gastro.2019.03.070. Epub 2019 Apr 12. Gastroenterology. 2019. PMID: 30986390 Review.
BEST PRACTICE ADVICE 4: The following transfusion thresholds for management of active bleeding or high-risk procedures may optimize clot formation in advanced liver disease: hematocrit 25%, platelet count >50,000, and fibrinogen >120 mg/dL. ...Neither is belie …
BEST PRACTICE ADVICE 4: The following transfusion thresholds for management of active bleeding or high-risk procedures may optimize clot for …
Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
Ay C, Pabinger I, Cohen AT. Ay C, et al. Thromb Haemost. 2017 Jan 26;117(2):219-230. doi: 10.1160/TH16-08-0615. Epub 2016 Nov 24. Thromb Haemost. 2017. PMID: 27882374 Review.
In this review, we discuss the epidemiology and burden of the disease, the pathophysiology of cancer-associated VTE, and the clinical treatment options for both primary prevention and acute treatment. ...Furthermore, blood count parameters (e.g. platelets …
In this review, we discuss the epidemiology and burden of the disease, the pathophysiology of cancer-associated VTE, and the clinical …
Toll-like receptor 7 regulates cardiovascular diseases.
Shafeghat M, Kazemian S, Aminorroaya A, Aryan Z, Rezaei N. Shafeghat M, et al. Int Immunopharmacol. 2022 Dec;113(Pt A):109390. doi: 10.1016/j.intimp.2022.109390. Epub 2022 Oct 29. Int Immunopharmacol. 2022. PMID: 36330918 Review.
Cardiovascular disease (CVD) is the major leading cause of morbidity and mortality worldwide. ...At the same time, they have a protective role against thrombosis by releasing granulocyte-macrophage colony-stimulating factors. The same two-sided effect was observe …
Cardiovascular disease (CVD) is the major leading cause of morbidity and mortality worldwide. ...At the same time, they have a protec …
Vascular endothelium - Gatekeeper of vessel health.
Cahill PA, Redmond EM. Cahill PA, et al. Atherosclerosis. 2016 May;248:97-109. doi: 10.1016/j.atherosclerosis.2016.03.007. Epub 2016 Mar 9. Atherosclerosis. 2016. PMID: 26994427 Free PMC article. Review.
The vascular endothelium is an interface between the blood stream and the vessel wall. Changes in this single cell layer of the artery wall are believed of primary importance in the pathogenesis of vascular disease/atherosclerosis. ...Compromised endothelial …
The vascular endothelium is an interface between the blood stream and the vessel wall. Changes in this single cell layer of the arter …
The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.
Rosińska J, Łukasik M, Kozubski W. Rosińska J, et al. Cardiovasc Drugs Ther. 2017 Dec;31(5-6):627-644. doi: 10.1007/s10557-017-6757-7. Cardiovasc Drugs Ther. 2017. PMID: 29164426 Free PMC article. Review.
Platelet-derived microvesicles (pMVs) are small, heterogeneous vesicles released from platelet membranes as a result of activation. ...The purpose of this review is to discuss the effects of drugs routinely used in primary and secondary prevention of v …
Platelet-derived microvesicles (pMVs) are small, heterogeneous vesicles released from platelet membranes as a result of …
CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.
Ramste M, Ritvos M, Häyrynen S, Kiiski JI, Niemi M, Sinisalo J. Ramste M, et al. Clin Transl Sci. 2023 Oct;16(10):2010-2020. doi: 10.1111/cts.13608. Epub 2023 Aug 16. Clin Transl Sci. 2023. PMID: 37551775 Free PMC article.
A cohort of prospective patients (n = 1972) with acute coronary syndrome (n = 1302) or symptomatic chronic coronary disease (n = 656) was followed for 365 days after hospitalization with information on purchased prescription drugs, hospital discharge, death, and gen …
A cohort of prospective patients (n = 1972) with acute coronary syndrome (n = 1302) or symptomatic chronic coronary disease (n = 656) …
Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
MacDougall K, Spyropoulos AC. MacDougall K, et al. Semin Respir Crit Care Med. 2021 Apr;42(2):308-315. doi: 10.1055/s-0041-1723018. Epub 2021 Feb 6. Semin Respir Crit Care Med. 2021. PMID: 33548931 Review.
Advances in the field of primary thromboprophylaxis in acutely-ill medical patients using validated VTE and bleeding risk assessment models have established key patient subgroups at high risk of VTE and low risk of bleeding that may benefit from both in-hospital and …
Advances in the field of primary thromboprophylaxis in acutely-ill medical patients using validated VTE and bleeding risk assessment …
Changes in the Proteome of Platelets from Patients with Critical Progression of COVID-19.
Wolny M, Rozanova S, Knabbe C, Pfeiffer K, Barkovits K, Marcus K, Birschmann I. Wolny M, et al. Cells. 2023 Sep 1;12(17):2191. doi: 10.3390/cells12172191. Cells. 2023. PMID: 37681923 Free PMC article.
Platelets, the smallest cells in human blood, known for their role in primary hemostasis, are also able to interact with pathogens and play a crucial role in the immune response. ...This study aims to further elucidate the role of platelets in COVID-19 …
Platelets, the smallest cells in human blood, known for their role in primary hemostasis, are also able to interact wit …
Pharmacotherapy of Raynaud's phenomenon.
Belch JJ, Ho M. Belch JJ, et al. Drugs. 1996 Nov;52(5):682-95. doi: 10.2165/00003495-199652050-00006. Drugs. 1996. PMID: 9118818 Review.
Indeed, the severity of symptoms often acts as the predictor for the much later onset of the associated systemic disease. ...These platelet clumps, white blood cells and damaged endothelium also release vasoactive/vasoconstrictive compounds whic …
Indeed, the severity of symptoms often acts as the predictor for the much later onset of the associated systemic disease. ...T …
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.
Valgimigli M, Wlodarczak A, Tölg R, Merkely B, Kelbæk H, Legutko J, Galli S, Godin M, Toth GG, Lhermusier T, Honton B, Dietrich PL, Stammen F, Ferdinande B, Silvain J, Capodanno D, Cayla G; Bioflow-DAPT Investigators. Valgimigli M, et al. Circulation. 2023 Sep 26;148(13):989-999. doi: 10.1161/CIRCULATIONAHA.123.065448. Epub 2023 Aug 25. Circulation. 2023. PMID: 37624364 Free PMC article. Clinical Trial.
The primary outcome was the composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year, and was powered for noninferiority, with an absolute margin of 4.1% at 1-sided 5% alpha. RESULTS: A total of 1948 patients at high bleeding risk were r …
The primary outcome was the composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year, and was pow …
140 results